NCT05221879 - Anti-factor Xa Based Venous Thromboembolism Prophylaxis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 23, 2019

Primary Completion Date

February 15, 2021

Study Completion Date

February 15, 2021

Conditions

Dose Adjustment of Enoxaparin in ICU Patients

Interventions

OTHER

Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a

We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.

Trial Locations (1)

Unknown

Meir Medical Center, Kfar Saba